Canaccord Genuity initiates coverage on Twist Bioscience with Buy rating

0 min read | Published on 15 Jun 2026, 10:10 PM |Updated on 15 Jun 2026, 10:10 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Canaccord Genuity analyst Kyle Mikson initiated coverage on Twist Bioscience with a Buy rating and a price target of $90, signaling a positive outlook for the stock.

*this image is generated using AI for illustrative purposes only.

Canaccord Genuity analyst Kyle Mikson has initiated coverage on Twist Bioscience with a Buy rating and announced a price target of $90. The rating reflects a positive outlook on the company's performance and future prospects.

Coverage Details

The initiation of coverage provides a new assessment of Twist Bioscience's market position. The price target of $90 indicates the firm's expectation for the stock's potential upside.

Analyst Perspective

Kyle Mikson's Buy rating suggests confidence in the company's ability to deliver value to shareholders. The detailed report supporting this rating likely outlines the key drivers behind the positive stance.

Twist Bioscience is now on the radar of investors following this coverage initiation. The price target serves as a benchmark for evaluating the stock's performance in the coming months.

What specific catalysts does Mikson identify that could drive Twist Bioscience's stock toward the $90 price target?

How might this new coverage impact investor sentiment and trading volume for Twist Bioscience in the short term?

What are the potential risks or challenges that could hinder the company from achieving the projected upside?

Piper Sandler initiates coverage on Twist Bioscience with Overweight rating

0 min read | Published on 11 Jun 2026, 04:52 PM |Updated on 11 Jun 2026, 04:52 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Piper Sandler analyst David Westenberg initiated coverage on Twist Bioscience with an Overweight rating and a price target of $85, indicating a positive outlook for the NASDAQ-listed biotechnology company.

*this image is generated using AI for illustrative purposes only.

Piper Sandler analyst David Westenberg has initiated coverage on Twist Bioscience with an Overweight rating and a price target of $85. The rating reflects a positive outlook on the company's performance and market position.

Analyst Rating and Price Target

The Overweight rating suggests that Twist Bioscience is expected to outperform the broader market or its sector peers. The assigned price target of $85 provides a specific valuation benchmark for investors.

Company Profile

Twist Bioscience is listed on the NASDAQ under the ticker symbol TWST. The company operates in the biotechnology sector, focusing on synthetic DNA and other genomic products.

What specific catalysts does Piper Sandler expect to drive Twist Bioscience's stock to the $85 price target?

How might Twist Bioscience's synthetic DNA technology impact the broader biotechnology sector in the coming years?

What are the potential risks or challenges that could hinder Twist Bioscience's ability to outperform its peers?